Stealth Bio Raises $100 Million from China Investors for Mitochondrial Candidates

Stealth Biotherapeutics, a Boston a clinical-stage biopharma that targets mitochondrial dysfunction, completed a $100 million financing in two convertible note rounds led by Nan Fung Technology's Pivotal Beta. Stealth will use the proceeds to continue a Phase IIb clinical trial of Stealth's lead compound, elamipretide, in intermediate dry age-related macular degeneration. Founded in 2007, Stealth is working on treatments for mitochondrial diseases that remain unmet needs. More details....

Share this with colleagues:

More From BioPortfolio on "Stealth Bio Raises $100 Million from China Investors for Mitochondrial Candidates"